Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 6/20 | 0.45 |
| ▸ | CCKBR | P32239 | 2/20 | 0.43 |
| ▸ | PRKACB | P22694 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 5/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 5/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | NPY4R | P50391 | 1/20 | 0.43 |
| ▸ | IL1RN | P18510 | 2/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19486139 | 1.00 | MC4R (0.45) | MC4RCCKBRPRKACBERAP2ERAP1 | |
| SCHEMBL13973857 | 0.99 | MC4R (0.46) | MC4RERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL13973837 | 0.99 | MC4R (0.46) | MC4RERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL12514972 | 0.99 | MC4R (0.46) | MC4RERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL13973759 | 0.99 | MC4R (0.46) | MC4RERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL19214489 | 0.96 | MC4R (0.46) | MC4RCCKBRPRKACBERAP2ERAP1 | |
| SCHEMBL12514971 | 0.96 | MC4R (0.44) | MC4RERAP2ERAP1LNPEPIL1RN | |
| SCHEMBL19219795 | 0.95 | MC4R (0.44) | MC4RCCKBRPRKACBERAP2ERAP1 | |
| SCHEMBL17949850 | 0.95 | ERAP2 (0.48) | MC4RERAP2ERAP1LNPEPIL1RN | |
| SCHEMBL19445778 | 0.94 | MAPT (0.41) | MC4RCCKBRPRKACBERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | MC4R 3911/4885CCKBR 1351/4885PRKACB 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.